$Invesco QQQ(QQQ)$ Yesterday was an interesting day for SLS.
The company filed an 8-K that further clarified the warrant situation.
On the same day, Memorial Sloan Kettering launched a major new campaign built around themes like "Treatment on a cellular level," "Hope on another level," and "Better, longer lives."
Dr. Angelos Stergiou publicly commented: "We are anxiously anticipating the REGAL data as we work together to transform the landscape of cancer care."
For those new, GPS was developed at Memorial Sloan Kettering and is currently being evaluated in the Phase 3 REGAL trial.
Meanwhile:
- The 80th event still hasn't occurred.
- REGAL remains significantly delayed.
- The warrant overhang continues to shrink.
- MSK and SELLAS keep emphasizing the same themes: hope, survival, and transforming cancer care.
The science came from MSK.
The trial is still running.
The clock is ticking.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
